Volume 2 Issue 2, March 1999

Editorial

• R Kirby
• H Scher
• M Brawer

Strategies for the chemoprevention of prostate cancer, Brussels, Belgium, October 30–31, 1998

• RS Kirby

Are we making an impact on prostate cancer?

• WD Figg
• JR Blumenfeld

Medical management of BPH: Where are we going?

• RS Kirby

Insulin-like Growth Factor (IGF) Network and Prostate Pathologies

• R Tatoud

Pathologic progression of autochthonous prostate cancer in the TRAMP model

• JR Gingrich
• RJ Barrios
• NM Greenberg

Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model

• BA Foster
• PJ Kaplan
• NM Greenberg

Estramustine in combination with vinblastine and mitomycin-C for patients with progressive androgen independent adenocarcinoma of the prostate

• RJ Amato
• C Bui
• CJ Logothetis

Antibiotic prophylaxis for prostate biopsy: benefits and costs

• P Larsson
• U Norming
• O Gustafsson

Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells

• V Väisänen
• J Lövgren
• K Pettersson

High energy transurethral thermotherapy in the treatment of benign prostatic hyperplasia: criteria to predict treatment outcome

• FCH d’Ancona
• EAE Francisca
• JJMCH de la Rosette

Erratum: Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly

• M Borre
• B Srausbol-Gron
• J Overgaard

GnRH Analogues and Prostate Cancer